Kalvista Pharmaceuticals Stock Performance
| KALV Stock | USD 9.33 0.01 0.11% |
The company secures a Beta (Market Risk) of 1.79, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kalvista Pharmaceuticals will likely underperform. At this point, Kalvista Pharmaceuticals has a negative expected return of -0.43%. Please make sure to verify Kalvista Pharmaceuticals' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Kalvista Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kalvista Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 0.78 | Five Day Return (9.34) | Year To Date Return (25.68) | Ten Year Return (88.40) | All Time Return (88.40) |
Last Split Factor 1:14 | Dividend Date 2016-11-22 | Last Split Date 2016-11-22 |
1 | KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 09/04/2024 |
2 | Disposition of 7352 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 12.1901 subject to Rule 16b-3 | 09/09/2024 |
3 | KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum | 09/26/2024 |
4 | KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema | 09/30/2024 |
5 | Acquisition by Unkart Edward W of 10000 shares of Kalvista Pharmaceuticals at 11.54 subject to Rule 16b-3 | 10/03/2024 |
6 | KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma Immunology | 10/18/2024 |
7 | Acquisition by Audhya Paul K. of 30613 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 10/28/2024 |
8 | KalVista Pharmaceuticals Announces Pricing of a 55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of 5 Million | 11/04/2024 |
9 | Vanguard Group Incs Strategic Acquisition in KalVista Pharmaceuticals Inc | 11/05/2024 |
10 | Insight into TANG CAPITAL MANAGEMENT LLCs Strategic Acquisition of KalVista Pharmaceuticals ... | 11/15/2024 |
11 | Disposition of 8077 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 9.2566 subject to Rule 16b-3 | 11/18/2024 |
12 | Acquisition by Brian Piekos of 100000 shares of Kalvista Pharmaceuticals at 11.87 subject to Rule 16b-3 | 11/20/2024 |
| Begin Period Cash Flow | 56.2 M | |
| Free Cash Flow | -89.7 M |
Kalvista |
Kalvista Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,306 in Kalvista Pharmaceuticals on August 24, 2024 and sell it today you would lose (373.50) from holding Kalvista Pharmaceuticals or give up 28.6% of portfolio value over 90 days. Kalvista Pharmaceuticals is currently does not generate positive expected returns and assumes 4.7344% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Kalvista, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kalvista Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kalvista Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kalvista Pharmaceuticals, and traders can use it to determine the average amount a Kalvista Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0906
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KALV |
Estimated Market Risk
| 4.73 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.43 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kalvista Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kalvista Pharmaceuticals by adding Kalvista Pharmaceuticals to a well-diversified portfolio.
Kalvista Pharmaceuticals Fundamentals Growth
Kalvista Stock prices reflect investors' perceptions of the future prospects and financial health of Kalvista Pharmaceuticals, and Kalvista Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kalvista Stock performance.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 272.95 M | ||||
| Shares Outstanding | 49.22 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 2.55 X | ||||
| Price To Sales | 107.42 X | ||||
| Gross Profit | (80.28 M) | ||||
| EBITDA | (134.28 M) | ||||
| Net Income | (126.64 M) | ||||
| Cash And Equivalents | 142.08 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 7.32 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 17.51 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (89.23 M) | ||||
| Earnings Per Share | (3.57) X | ||||
| Market Capitalization | 440.97 M | ||||
| Total Asset | 235.4 M | ||||
| Retained Earnings | (469.73 M) | ||||
| Working Capital | 202.88 M | ||||
| Current Asset | 54.95 M | ||||
| Current Liabilities | 4.27 M | ||||
About Kalvista Pharmaceuticals Performance
Evaluating Kalvista Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Kalvista Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kalvista Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (9.33) | (8.87) | |
| Return On Tangible Assets | (0.54) | (1.09) | |
| Return On Capital Employed | (0.66) | 18.02 | |
| Return On Assets | (0.54) | (1.09) | |
| Return On Equity | (0.61) | 0.16 |
Things to note about Kalvista Pharmaceuticals performance evaluation
Checking the ongoing alerts about Kalvista Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kalvista Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kalvista Pharmaceuticals generated a negative expected return over the last 90 days | |
| Kalvista Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (126.64 M) with loss before overhead, payroll, taxes, and interest of (80.28 M). | |
| Kalvista Pharmaceuticals currently holds about 142.08 M in cash with (89.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.78. | |
| Kalvista Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Brian Piekos of 100000 shares of Kalvista Pharmaceuticals at 11.87 subject to Rule 16b-3 |
- Analyzing Kalvista Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kalvista Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Kalvista Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kalvista Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kalvista Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kalvista Pharmaceuticals' stock. These opinions can provide insight into Kalvista Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.